采用单中心、随机、开放、两周期交叉、单剂量给药设计比较空腹和餐后给药条件下，浙江金必康医药科技有限公司提供的苯溴马隆片（规格：50 mg）与トーアエイヨー株式会社持证的苯溴马隆片（商品名：Urinorm®，规格：50 mg）在中国健康人群中吸收程度和吸收速度的差异，并评价浙江金必康医药科技有限公司提供的苯溴马隆片（规格：50 mg）的安全性。

[Translation]

A single-center, randomized, open, two-period crossover, single-dose design was used to compare the differences in absorption extent and absorption rate between benzbromarone tablets (specification: 50 mg) provided by Zhejiang Jinbikang Pharmaceutical Technology Co., Ltd. and benzbromarone tablets (trade name: Urinorm®, specification: 50 mg) certified by Toaieyo Co., Ltd. in healthy Chinese people under fasting and postprandial administration conditions, and to evaluate the safety of benzbromarone tablets (specification: 50 mg) provided by Zhejiang Jinbikang Pharmaceutical Technology Co., Ltd.

Start Date05 Nov 2024

Sponsor / Collaborator

Zhejiang Jinbikang Pharmaceutical Technology Co., Ltd

CTR20243517 / Active, not recruitingNot Applicable

健康受试者空腹和餐后单次口服苯溴马隆片的随机、开放、单剂量、两制剂、两序列、两周期、双交叉设计的生物等效性试验。

[Translation] A randomized, open-label, single-dose, two-formulation, two-sequence, two-period, double-crossover bioequivalence study of single oral administration of benzbromarone tablets on an empty stomach or after a meal in healthy volunteers.

主要研究目的：研究空腹和餐后状态下单次口服受试制剂苯溴马隆片（规格：50mg，漯河市汇创医药有限公司持证）与参比制剂苯溴马隆片（Urinorm®，规格：50mg，トーアエイヨー株式会社持证）在健康成年受试者体内的药代动力学，评价空腹和餐后状态口服两种制剂的生物等效性。次要研究目的：评价健康受试者在空腹和餐后状态下，单次口服苯溴马隆片受试制剂和参比制剂后的安全性。

[Translation]

The main purpose of the study is to study the pharmacokinetics of the test preparation benzbromarone tablets (specification: 50 mg, licensed by Luohe Huichuang Pharmaceutical Co., Ltd.) and the reference preparation benzbromarone tablets (Urinorm®, specification: 50 mg, licensed by Toeiyo Co., Ltd.) in healthy adult subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations in the fasting and fed state. The secondary purpose of the study is to evaluate the safety of the test preparation and reference preparation of benzbromarone tablets in healthy subjects after a single oral administration in the fasting and fed state.

Start Date26 Sep 2024

Sponsor / Collaborator

Luo He Shi Hui Chuang Yi Yao You Xian Gong Si

CTR20243233 / CompletedNot Applicable

试验专业题目苯溴马隆片在健康受试者中的单中心、单剂量、2制剂、2周期、2序列、开放、随机、交叉的平均生物等效性试验

[Translation] A single-center, single-dose, 2-formulation, 2-cycle, 2-sequence, open, randomized, crossover average bioequivalence study of benzbromarone tablets in healthy subjects

主要研究目的：研究健康受试者空腹/餐后状态下单次口服受试制剂苯溴马隆片（规格：50mg，北京福元医药股份有限公司生产）与参比制剂苯溴马隆片（规格：50 mg，商品名：Urinorm，トーアエイヨー株式会社生产、持证）在健康受试者体内的药代动力学，评价空腹/餐后状态下口服两种制剂的生物等效性。次要研究目的：观察受试制剂和参比制剂在中国健康受试者中的安全性。

[Translation]

Main study objectives: To study the pharmacokinetics of the test preparation benzbromarone tablets (specification: 50 mg, produced by Beijing Fuyuan Pharmaceutical Co., Ltd.) and the reference preparation benzbromarone tablets (specification: 50 mg, trade name: Urinorm, produced and certified by Toeiyo Co., Ltd.) in healthy subjects after a single oral administration in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. Secondary study objectives: To observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.

Start Date04 Sep 2024

Sponsor / Collaborator

Beijing Winsunny Pharmaceutical Co., Ltd.

100 Clinical Results associated with Benzbromarone

100 Translational Medicine associated with Benzbromarone

100 Patents (Medical) associated with Benzbromarone

674

Literatures (Medical) associated with Benzbromarone

01 Mar 2025·BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Identification of N-phenyl-N-(quinolin-4-yl) amino carboxylic acids as URAT1 inhibitors with hypouricemic effects

Article

Author: Hou, Xianxin ; Zhang, Lei ; Yang, Ying ; Xiao, Zhiyan ; Shao, Mengjie

Urate transporter 1 (URAT1) is a therapeutic target for the treatment of hyperuricemia and gout. However, the application of currently marketed URAT1 inhibitors is hampered by insufficient efficacy and poor safety profiles. A series of N-phenyl-N-(quinolin-4-yl) amino carboxylic acids were designed by adopting strategies of molecular hybridization, scaffold hopping, and functional variation. Most compounds showed apparent inhibitory activity against URAT1, and the most active compound 7 exhibited an IC₅₀ of 0.18 μ M, which was comparable to the clinically available drug benzbromarone (IC₅₀ = 0.39 μ M). When tested in parallel with benzbromarone, compound 7 showed significant uric acid-lowering effect in a hyperuricemia zebrafish model induced by potassium oxonate and xanthine sodium salt. Compound 7 was also more metabolically stable than benzbromarone in mouse liver microsomes. The results suggested potential therapeutic benefits of these compounds in the treatment of hyperuricemia and gout.

13 Dec 2024·ACS Infectious Diseases

Repurposing Benzbromarone as an Antibacterial Agent against Gram-Positive Bacteria

Article

Author: Huang, Xuancheng ; Yu, Zhijian ; Wen, Zewen ; Li, Peiyu ; Wang, Xueting ; Li, Congcong ; Meng, Qingyin ; Liu, Xiaoju

The rise of antibiotic-resistant Gram-positive pathogens, particularly methicillin-resistant Staphylococcus aureus (MRSA), presents a significant challenge in clinical settings. There is a critical need for new antibacterial agents to combat these resistant strains. Our study reveals that the uricosuric drug Benzbromarone (Benz) exhibits potent antibacterial activity against Gram-positive pathogens, with minimum inhibitory concentrations (MICs) ranging from 8 to 32 μg/mL and minimum bactericidal concentrations (MBCs) ranging from 32 to 128 μg/mL against clinical isolates of S. aureus, S. epidermidis, Enterococcus faecalis, and Streptococcus agalactiae. Furthermore, Benz significantly inhibits biofilm formation at subinhibitory concentrations and eradicates mature biofilms at higher concentrations. Benz also suppresses the hemolytic activity of S. aureus, indicating its potential to reduce virulence. Proteomic and in vitro induced resistance analyses indicate that Benz inhibits protein synthesis and turnover. Additionally, Benz induces membrane depolarization and increases membrane permeability, likely by targeting the membrane phospholipid phosphatidylethanolamine (PE). In the mouse wound infection model, Benz promotes wound healing and significantly reduces bacterial load. These findings suggest that Benz is a promising candidate for developing new antibacterial therapies against Gram-positive bacterial infections.

01 Dec 2024·PHYTOTHERAPY RESEARCH

α‐Mangostin Attenuates Blood Pressure and Reverses Vascular Remodeling by Balancing ACE/AT1R and ACE2/Ang‐(1–7)/MasR Axes in Ang II‐Infused Hypertensive Mice

Article

Author: Xue, Qi‐Qi ; Li, Ming‐Xuan ; Li, Yan ; Zhang, Dong‐Yan ; Liu, Chu‐Hao

ABSTRACT:

Hyperuricemia is a common comorbidity of hypertension and probably has a causal relationship with hypertension. Alpha‐mangostin (α‐MG) has been reported to have uric acid lowering effect. This study aimed to investigate the dual effects of α‐MG on blood pressure (BP) and uric acid levels in angiotensin II (Ang II)‐infused hypertensive mice. Male C57BL/6 mice were randomized into five groups: control, Ang II infusion (500 ng/kg/min for 2 weeks), Ang II infusion with gavage administration of α‐MG 4.0 and 8.0 mg/kg and benzbromarone (25 mg/kg) respectively. BP, uric acid levels, vascular structure and function, and renin–Ang II system expressions in the aorta were assessed. Treatment with α‐MG reduced BP, improved endothelial relaxation, and reversed aortic wall thickening and collagen deposition in Ang II‐induced hypertensive mice. It also downregulated Ang II receptor 1 (AT1R) and angiotensin converting enzyme (ACE) expression, while upregulating ACE2, Mas receptor (MasR), and angiotensin (1–7) in the aorta. Moreover, α‐MG demonstrated a significant enhancement in uric acid clearance and reduction in serum uric acid levels. Conversely, benzbromarone did not result in a decrease in BP, indicating that the hypotensive effect of α‐MG may not be necessarily dependent on its urate‐lowering properties. α‐MG can attenuate Ang II‐induced hypertension and reverse vascular remodeling, potentially by balancing the ACE/Ang II/AT1R axis and the ACE2/Ang‐(1–7)/MasR axis. Our findings provide insights into α‐MG as a novel anti‐hypertensive drug especially in patients with hyperuricemia.

News (Medical) associated with Benzbromarone

03 Dec 2024

·www.businesswire.com

Atom Therapeutics and China Medical System Holdings Enter Exclusive Commercialization Agreement for Lingdolinurad (ABP-671) to Treat Chronic Gout and Hyperuricemia

ZHEJIANG, China--( BUSINESS WIRE )--Atom Therapeutics Co. Ltd (Atom Therapeutics), a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, announced today the company entered into an exclusive commercialization collaboration agreement with a subsidiary of China Medical System Holdings Ltd (CMS) for lingdolinurad (ABP-671), a novel oral small molecule URAT1 inhibitor for the treatment of chronic gout and hyperuricemia, in mainland China, Hong Kong Special Administrative Region and Macao Special Administrative Region. Atom Therapeutics and CMS will execute a Contract Sales Organization (CSO) business model. Under the agreement, Atom Therapeutics will receive a substantial sum from CMS through upfront and milestone payments, and will pay marketing and sales service fees to CMS. Lingdolinurad is expected to generate substantial income and revenue from the sales collaborated with CMS. This event marks a significant advancement for Atom Therapeutics in the commercialization of ABP-671. Atom Therapeutics is currently conducting multi-center Phase 2b/3 clinical trials of lingdolinurad worldwide, including in China and the United States. Lingolinurad reduces renal re-absorption of uric acid by inhibiting URAT1 (urate anion transporter 1). Results from multiple clinical trials have demonstrated that lingdolinurad is safe and effective at multiple dose levels (from 1 mg to 12 mg). The 2 mg once-daily tablet is expected to be as effective as benzbromarone (80 mg) and febuxostat (80 mg). The efficacy of lingdolinurad is maintained for over 24 hours without significant safety concerns, positioning it as a potentially safer and more effective treatment option for patients with chronic gout and hyperuricemia. CMS is a platform company linking pharmaceutical innovation and commercialization with a strong product lifecycle management capability, outstanding market promotion capabilities, and extensive commercialization experience. Through this collaboration, Atom Therapeutics will leverage the broad market channels and rich commercialization experience of CMS to achieve rapid promotion and broad clinical application of ABP-671 following its launch. Atom Therapeutics CEO, Chairman and Founder William Dongfang Shi, Ph.D., commented, “This collaboration represents a deep integration of our two companies' business operations and strategic initiatives. We look forward to advancing the implementation and application of ABP-671 through this partnership, delivering more effective treatment options for patients with gout and hyperuricemia as soon as possible.” About Atom Therapeutics Atom Therapeutics Co., Ltd (originally named Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd) officially changed its name on October 8, 2024. Atom Therapeutics is a fast-growing innovative drug company focused on development of best-in-class small molecule therapeutics for treatment of inflammatory and metabolic diseases. The company’s lead product, lingdolinurad, is in late-stage clinical development for treatment of chronic gout. Another small molecule ABP-745, for anti-inflammatory and autoimmune conditions, has completed Phase 1 clinical trials in the US and demonstrated good pharmacokinetics and safety, and will enter Phase 2 clinical trials soon. For more information, please visit: https://www.atombp.com or atombp.us . About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class and best-in-class innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a "bridgehead" for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group. For more information, please visit: https:/veb.cms.net.cn.

Phase 1License out/inClinical Result

16 Oct 2023

·www.biospace.com

Atom Bioscience Raises $83M in a D-Round Financing to Support Global Pivotal Clinical Trials of ABP-671, a New Treatment for Chronic Gout

JIANGSU, China--(BUSINESS WIRE)-- Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, announced today completion of a D-round financing of approximately $83 million (CNY 600 million) for completion of global pivotal clinical trials of ABP-671, its unique orally administered URAT1 inhibitor for chronic gout. The funds also will be used to advance to clinical stage the company’s innovative pipeline of drugs for inflammatory and metabolic diseases. This round of financing includes new and existing investors and was led by Kaitai Capital. Other investors include Fortune Capital, Huajin Investment, Unifortune and NNFE Investment. After this round of financing, Atom has raised a total of nearly $165 million. "We appreciate the support of every investment institution involved in the D-round financing and previous investors,” said Dr. William Dongfang Shi, CEO, Chairman and Founder of Atom Bioscience. “We are honored to have their trust as we strive to promote innovative best-in-class drugs benefiting gout patients worldwide.” Chronic gout is caused by long-term hyperuricemia (serum uric acid (sUA) > 7 mg/dL or 420 μmol/L). More than 50 million patients suffer from gout worldwide and nearly 10 million in the U.S. Globally, there are more than 200 million people with hyperuricemia. Aside from the acute painful flare-ups associated with gout, the disease seriously affects people's quality of life and can increase the probability of sudden cardiac death and kidney function injury. The performance of existing gout drugs is far from meeting clinical needs. The drugs have poor efficacy and pose serious safety issues, such as leading to kidney failure, sudden cardiac death, or severe liver toxicity. ABP-671 reduces sUA levels by inhibiting renal urate transporter 1 (URAT1), resulting in normal excretion of urate in urine. Its clinical primary endpoint is to reduce sUA to < 6 mg/dL (360 μmol/L) and in previous clinical trials ABP-671 has demonstrated good efficacy, safety and tolerability. In two Phase 2 clinical trials of ABP-671 at doses ranging from 1 mg to 12 mg once a day, ABP-671 at a dose of 1 mg had showed a substantial reduction of sUA. At doses of 6 mg and 8 mg, 100% of subjects achieved the primary clinical end point of < 6 mg/dL. Notably, 100% of subjects experienced sUA levels of < 5 mg/dL (300 μmol/L), and there were 57% and 87.5% of subjects with sUA levels < 4 mg/dL (240 μmol/L), respectively. Some subjects had sUA levels < 3 mg/dL (180 μmol/L). At a dose of 12 mg of ABP-671, 100% of the subjects achieved sUA levels < 4 mg/dL. The two studies showed efficacy of ABP-671 can be maintained up to 24 hours with once daily dosing, and there were no significant adverse effects (AEs) compared to the placebo group. Maintaining sUA levels of 5 mg/dL to 4 mg/dL in gout patients is recommended by many national gout treatment guidelines. At these levels gout tophi are re-dissolved, tophi size and quantity are reduced and eventually acute gout attacks are reduced. This is difficult for most market drugs to achieve. “In terms of safety, ABP-671 is well tolerated. Its adverse events of ABP-671 were mostly grade 1 (mild and generally not bothersome), and the incidence is comparable to that of the placebo group,” said Dr. Shi. “No severe adverse events have occurred with ABP-671 at the doses tested.” He also observed, “A Human Mass Balance study, which evaluates how drugs are absorbed, metabolized and excreted, showed that ABP-671 is mostly excreted in its original form and does not produce any similar metabolites seen with benzbromarone (a currently marketed drug for gout treatment) which causes severe liver toxicity.” Dr. Shi added, “All subjects taking ABP-671 had a significant decrease in their sUA levels, therefore, we also plan to investigate ABP-671 for the treatment of refractory gout. In addition, we submitted a Pre-IND application to the U.S. FDA in August for ABP-745, which is used to treat inflammation and acute gout. We expect to submit the IND application in the U.S. and China in November.” About Atom Bioscience Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd.) is a fast-growing innovative drug company, focused on development of best-in-class small molecule therapeutics for treatment of inflammatory and metabolic diseases. The company’s lead product, ABP-671, is in clinical development for treatment of chronic gout. Another small molecule ABP-745 has shown significant efficacy and good safety in animal models of anti-inflammation, and is expected to be in Phase 1 clinical trials soon. For more information, please visit: or atombp.us. View source version on businesswire.com: Contacts Business Development Contact: Roy J. Wu, MBA Sr. Vice President, Business Development Atom Bioscience and Pharmaceutical Co., Ltd Email: roy.wu@atombp.com Source: Atom Bioscience View this news release online at:

Clinical ResultPhase 2INDPhase 1

09 Oct 2023

·www.biospace.com

Atom Bioscience Doses First Patient in Phase 2b/3 Clinical Trial of a New Treatment for Chronic Gout

JIANGSU, China--(BUSINESS WIRE)-- Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today the first patient has been dosed in a Phase 2b/3 clinical trial of ABP-671, a novel orally administered URAT1 inhibitor, for the treatment of chronic gout. The multicenter, randomized, double-blind trial will enroll 580 patients worldwide, including the U.S. The results from Part 1 of the study are expected to be available in Q4/2024. Part 1 will evaluate the safety and efficacy of ABP-671 at different doses and regimens. Part 2 of the study will be a confirmatory study for dosing regimens of ABP-671 selected from Part 1. “Gout affects more than 50 million people worldwide and is on the rise in many countries,” said Atom Bioscience CEO, Chairman and Founder Dr. William Dongfang Shi. "The need for a safe and effective treatment has never been greater. We believe our unique, potent, orally-available drug, ABP-671, will be a better treatment option for patients as suggested by currently available safety and efficacy data.” ABP-671 works by reducing the abnormally high levels of serum uric acid (sUA) and increasing excretion of urate through urine. Gout is one of the most common types of inflammatory arthritis. It is caused by long-term hyperuricemia, an excessive concentration of serum uric acid (sUA) greater than 7 mg/dL (420 μmol/L). Gout seriously affects patients’ quality of life and is associated with other serious comorbidities, including kidney function injury, increasing the probability of sudden cardiac death. Existing drugs for treating chronic gout have poor efficacy and pose serious safety issues, such as leading to kidney failure, sudden cardiac death, or severe liver toxicity. In two Phase 2 clinical trials of ABP-671 at doses ranging from 1 mg to 12 mg once a day, ABP-671 at a dose of 1 mg had showed a substantial reduction of sUA. 100% of subjects with levels of sUA achieved the primary endpoint of < 6 mg/dL at doses of 6 mg and 8 mg. Notably, 100% of subjects also experienced sUA levels of < 5 mg/dL, and there were 57% and 87.5% of subjects with sUA levels < 4 mg/dL (240 μmol/L), respectively. Some subjects had sUA levels < 3 mg/dL (180 μmol/L). At a dose 12 mg of ABP-671, 100% of the subjects achieved sUA levels <4 mg/dL. The two studies showed that the efficacy of ABP-671 can be maintained up to 24 hours with once daily dosing, and there were no significant adverse events compared to the placebo group. “In terms of safety, ABP-671 is well tolerated. Its adverse events were mostly grade 1 (mild and generally not bothersome), and the incidence is comparable to that of the placebo group,” said Dr. Shi. “No severe adverse events have occurred with ABP-671 at the dose tested.” Dr. Shi also added, “A Human Mass Balance study, which evaluates how drugs are absorbed, metabolized and excreted, showed that ABP-671 is mostly excreted in its original form and does not produce any of similar metabolites seen with benzbromarone (a currently marketed drug for gout treatment) which causes severe liver toxicity.” Maintaining sUA levels of 5 mg/dL to 4 mg/dL in gout patients is recommended by many national gout treatment guidelines. At these levels gout tophi are re-dissolved, tophi size and quantity are reduced and eventually acute gout attacks are reduced. This is difficult for most market drugs to achieve. About Atom Bioscience Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd.) is a fast-growing innovative drug company, focused on development of best-in-class small molecule therapeutics for treatment of inflammatory and metabolic diseases. The company’s lead product, ABP-671, is in clinical development for treatment of chronic gout. Another small molecule ABP-745 has shown significant efficacy and good safety in animal models of anti-inflammation, and is expected to be in phase 1 clinical trials soon. For more information, please visit: or atombp.us. View source version on businesswire.com: Contacts Business Development Contact: Roy J. Wu, MBA Sr. Vice President, Business Development Atom Bioscience and Pharmaceutical Co., Ltd Email: roy.wu@atombp.com Phase 2b/3 clinical trial information: ( ; NCT05818085) Source: Atom Bioscience View this news release online at:

Clinical ResultPhase 2Phase 1

100 Deals associated with Benzbromarone

External Link

KEGG	Wiki	ATC	Drug Bank
D01056	Benzbromarone	M04AB03	DB12319

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hyperuricemia	JP	Pfizer Japan, Inc.	04 Nov 1986
Gout	JP	TOA Eiyo Ltd.	01 Aug 1978
Hypertension	JP	TOA Eiyo Ltd.	01 Aug 1978

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EULAR2024	Not Applicable	Chronic tophaceous gout	15	Benzbromarone	lmdobccjem(jyakglgpab) = kuwcdbzexn wjndqzdflx (ilqunfvqnl, 1.2 - 2.9)	Positive	05 Jun 2024
				Febuxostat	lmdobccjem(jyakglgpab) = lmopqqhzaw wjndqzdflx (ilqunfvqnl, 1.1 - 3.6)
EULAR2023	Not Applicable	Gout	98	Benzbromarone	azzvzmufdh(ftanepfclo) = dvkdgdtdsd nbfwvnryyv (fgkqkugtyk, 1.0) View more	-	31 May 2023
ASN2022	Not Applicable	Hyperuricemia \| Hypertension \| Chronic Kidney Diseases hyperuricemia \| hypertension	96	Febuxostat	ujxeexnueq(puabqaswdo) = qiphzlwbgi uuiydczvxj (ajhfdktnqm, -2.00 to 1.55)	Negative	05 Nov 2022
				Benzbromarone	-
RBR-5wvg53s (ERS2022)	Phase 2	Pulmonary Cystic Fibrosis Adjuvant TMEM16A \| CFTR	9	Benzbromarone 100 mg/day	axilnigydb(zldxbwnldn) = alvyhbqghe slfqdchuos (aspfpmzsqv, 3 - 9)	Positive	04 Sep 2022
ATS2021	Not Applicable	-	-	Albuterol	cahicvztsr(estilnolgv) = pqgezgpxjw jvlfxhqfyk (mmgivtafok, 4.19)	-	03 May 2021
				Benzbromarone	cahicvztsr(estilnolgv) = vkhjawjerr jvlfxhqfyk (mmgivtafok, 7.75)
ESC2017	Not Applicable	Chronic Kidney Diseases	120	Urate lowing therapy (ULT) group	xygqjbivxg(vwtgtnicha) = rjurhtuill egpwneoevu (phkxeyelfy ) View more	-	28 Aug 2017
				Control group	xygqjbivxg(vwtgtnicha) = wmcnfevmfy egpwneoevu (phkxeyelfy ) View more
EULAR2010	Not Applicable	Gout PTX3	-	Benzbromarone	kjdyhfzbfd(uxcehpdikx) = imsgjljavs rqwcfpycph (jnqcguukdy )	Positive	16 Jun 2010
				Allopurinol	kjdyhfzbfd(uxcehpdikx) = gqvwwulfxc rqwcfpycph (jnqcguukdy )
EULAR2010	Not Applicable	Gout allantoin	-	Benzbromarone (Patients with gout)	boawqfjoah(kbbprivkxq) = qnujhejkep vjbwibggev (sssnasprtv, 3.5) View more	-	16 Jun 2010
				Benzbromarone (Healthy subjects)	boawqfjoah(kbbprivkxq) = xqfwgwqebc vjbwibggev (sssnasprtv, 2.3) View more
NCT00422318 (Pubmed \| Circ Heart Fail)	Phase 4	Heart Failure	82	Benzbromarone	xkxcbzfppk(mczsinipgo) = gaynvujypx ijerarggqk (porbkvdyzk ) View more	-	01 Jan 2010
				Placebo	xkxcbzfppk(mczsinipgo) = kngihjmrja ijerarggqk (porbkvdyzk ) View more
EULAR2007	Not Applicable	Gout Second line	-	Allopurinol 300 mg	zldeiiafgy(fgxmidolgr) = 10% stopped allopurinol because of adverse drug reactions fqqxewlisb (ngaxhclpck )	-	13 Jun 2007

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis